Supporting information

Cu(I)-Catalyzed Tandem Decarboxylative/C-H activation Coupling reaction of Cyclic diketone, proline and alkyne: Synthesis of αalkynylated pyrrolidine-oxyindoles

Atul Kumar*, Mukesh Kumar, Lalit Prakssh Gupta and Maneesh Kumar Gupta Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow-226001, India

General Information: All the reagents and solvents were purchased from Sigma-Aldrich or Merck chemical Co. and were used directly without any further purification. Organic solutions were concentrated under reduced pressure on a Büchi rotary evaporator. The progress of reaction was checked by thin-layer chromatography. The plates were visualized first with UV illumination followed by iodine. ¹HNMR spectra were recorded at 200 or 300 MHz using Brucker DRX-200 or 300 spectrometer and are reported in parts per million (ppm) on the δ scale relative to tetramethylsilane as an internal standard. Coupling constants (*J*) reported in Hz. ¹³CNMR spectra were recorded at 50 or 75 MHz. Mass spectra were obtained using JEOL SX-102 (ESI) instrument. Elemental analysis was performed using a Perkin-Elmer autosystem XL analyzer.

Typical Procedure for the Synthesis of α-alkynylated pyrrolidine-oxyindoles (4a-n): Typical procedure for the synthesis of α-alkynylated pyrrolidine-oxyindole **4a**, CuI (0.038 mg, 20 mol %) was added to a solution of proline (**2a**, 1.5 mmol, 0.173 mg) in acetinitrile (5 mL). The mixture was stirred for 10 min under nitrogen atmosphere at room temperature, and then isatin (**1a**, 1 mmol, 0.147 mg), and alkyne (**3a**, 2 mmol, 0.204 mg) was added to the reaction mixture and reaction was heated in a oil bath at 100 0 C with stirring under nitrogen atmosphere until completion of reaction monitored through TLC. Upon completion (6-8 h) of the reaction, the mixture was then cooled to room temperature and filtered on celite. The filtrate was concentrated under reduced pressure to give the crude material, which was purified by column chromatography on silica gel (eluent: EtOAc/hexane), and afforded α-substituted pyrrolidine-oxyindole **4a-n** in good to excellent yield.

Typical Procedure for the Synthesis 6a-b: CuI (0.038 mg, 20 mol %) was added to a solution of proline (**2a**, 1.5 mmol, 0.173 mg) in acetinitrile (5 mL). The mixture was stirred for 10 min under nitrogen atmosphere at room temperature, and then added acenaphthylene-1,2-dione **5a** (1 mmol, 0.182 mg), and phenyl acetylene (**3a**, 2 mmol, 0.204 mg). The reaction was then heated at 100 0 C in a oil bath with stirring under nitrogen atmosphere until completion of reaction monitored through TLC. Upon completion (6-8 h) of the reaction, the mixture was then cooled to room temperature and filtered on celite.

The filtrate was concentrated under reduced pressure to give the crude material, which was purified by column chromatography on silica gel (eluent: EtOAc/hexane), and afforded desired **6a-b** in good to excellent yield.

Typical Procedure for the Synthesis of 8a-c: CuI (0.038 mg, 20 mol %) was added to a solution of proline (**2a**, 1.5 mmol, 0.173 mg) in acetinitrile (5 mL). The mixture was stirred for 10 min under nitrogen atmosphere at room temperature, and then added aceanthrylene-1,2-dione **7a** (1 mmol, 0.232 mg), and phenyl acetylene (**3a**, 2 mmol, 0.204). The reaction was then heated in at 100 $^{\circ}$ C in a oil bath with stirring under nitrogen atmosphere until completion of reaction monitored through TLC. Upon completion (6-8 h) of the reaction, the mixture was then cooled to room temperature and filtered on celite. The filtrate was concentrated under reduced pressure to give the crude material, which was purified by column chromatography on silica gel (eluent: EtOAc/hexane), and afforded desired **8a-c** in good to excellent yield.

Typical Procedure for the Synthesis of 10: CuI (0.038 mg, 20 mol %) was added to a solution of proline (**2a**, 1.5 mmol, 0.173 mg) in acetinitrile (5 mL). The mixture was stirred for 10 min under nitrogen atmosphere at room temperature, and then added 1H-indene-1,2,3-trione **9a** (1 mmol, 0.160 mg), and phenyl acetylene (**3a**, 2 mmol, 0.204). The reaction was then heated in at 100 0 C in a oil bath with stirring under nitrogen atmosphere until completion of reaction monitored through TLC. Upon completion (6-8 h) of the reaction, the mixture was then cooled to room temperature and filtered on celite. The filtrate was concentrated under reduced pressure to give the crude material, which was purified by column chromatography on silica gel (eluent: EtOAc/hexane), and afforded desired **10** in good to excellent yield.

Characterization Data of Synthesized compounds

```
3-(2-(Phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4a): Physical state: solid. <sup>1</sup>H NMR (300 MHz,
```



CDCl₃) δ (**ppm**): 1.91-1.60 (m, 3H), 2.17-2.14 (m, 1H), 2.80 (t, J = 7.2 Hz, 2H), 4.80 (t, J = 7.1 Hz, 1H), 6.60 (s, 1H), 7.12-6.94 (m, 8H), 7.23 (d, J = 7.1 Hz, 1H), 9.34 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (**ppm**): 26.5, 33.3, 48.5, 70.9, 79.2, 110.6, 113.6, 121.6, 125.6, 126.4, 127.1, 127.8, 129.2, 132.4, 132.8, 138.7, 139.4, 141.5, 181.1; **IR** (**KBr**): 3480, 2921, 3021, 2135, 1678 cm⁻¹; **ESI**

MS (m/z): 303 $(M+H)^+$. Anal. Calcd. for C₂₀H₁₈N₂O: C, 79.44; H, 6.00; N, 9.26; Found: C, 79.48; H, 6.02; N, 9.22.

5-Chloro-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4b): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.60-150 (m, 1H), 1.86-1.82 (m, 2H), 2.11-2.04 (m, 1H), 2.69-2.64 (m, 2H), 4.66 (t, J = 6.9Hz, 1H), 6.52 (s, 1H), 6.87-6.81 (m, 2H), 7.08-6.96 (m, 2H), 7.15 (dd, J = 8.2Hz, 8.3Hz, 4H), 9.99 (s, 1H); ¹³C

NMR (75 MHz, CDCl₃) δ (ppm): 28.9, 31.0, 48.2, 70.6, 111.3, 125.5, 125.7, 126.1, 127.3, 128.0, 128.4, 129.2, 132.8, 133.0, 138.5, 138.9, 141.4, 178.6; **IR (KBr):** 3440, 2910, 3034, 2201, 1680 cm⁻¹; **ESI** MS (*m/z*): 337 (M+H)⁺. Anal. Calcd. for C₂₀H₁₇ClN₂O: C, 71.32; H, 5.09; N, 8.32; Found: C, 71.34; H, 5.07; N, 8.33.

5-Bromo-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4c): Physical state: solid; ¹H NMR (300



MHz, DMSO-*d*₆) δ (**ppm**): 0.85-0.55 (m, 2H), 1.39-1.22 (m, 4H), 3.23 (t, J = 7.2Hz, 1H), 5.51 (s, 1H), 5.66 (d, J = 8.2Hz, 1H), 5.77-5.75 (m, 1H), 5.84 (s, 1H), 5.95 (d, J = 5.9Hz, 3H), 6.22 (dd, J = 8.2Hz, 8.2Hz, 1H), 9.36 (s, 1H); ¹³C NMR (50 MHz, DMSO-*d*₆) δ (ppm): 26.1, 30.3, 47.8, 70.3,

77.6, 111.6, 112.5, 125.1, 127.1, 127.9, 128.5, 128.6, 132.0, 132.7, 133.2, 138.0, 141.6, 177.7; **IR** (**KBr**): 3390, 2919, 3019, 2224, 1665 cm⁻¹; **ESI** MS (m/z): 381 (M+H)⁺. Anal. Calcd. for C₂₀H₁₇BrN₂O: C, 63.00; H, 4.49; N, 7.35; Found: C, 63.05; H, 4.43; N, 7.36.

5-Nitro-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4d): Physical state: solid; ¹H NMR (300



MHz, DMSO-*d*₆) δ (**ppm**): 0.58-0.36 (m, 3H), 0.86 (br, s, 1H), 1.65-1.60 (m, 2H), 3.29 (br, s, 1H), 5.59-5.58 (br, s, 1H), 5.77 (t, *J* = 2.6Hz, 2H), 5.96 (t, *J* = 6.4Hz, 4H), 6.51 (br, s, 1H), 7.03-6.99 (m, 1H), 10.03 (s, 1H); ¹³C **NMR (75 MHz, DMSO-***d*₆) δ (**ppm**): 26.6, 30.8, 48.6, 70.9, 77.8, 110.5,

121.6, 125.6, 127.2, 127.5, 127.7, 128.6, 133.0, 134.5, 138.1, 141.9, 149.3, 179.0; **IR** (**KBr**): 3460, 2930, 3034, 2205, 1666 cm⁻¹; **ESI** MS (*m*/*z*): 348 (M+H)⁺. Anal. Calcd. for C₂₀H₁₇N₃O₃: C, 69.15; H, 4.93; N, 12.10; Found: C, 69.18; H, 4.89; N, 12.12.

5-Fluoro-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4e): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.96-1.88 (m, 2H), 2.22-2.12 (m, 2H), 2.78 (t, J = 6.6Hz, 2H), 4.77 (t, J = 6.7Hz, 1H), 6.60 (br, 1H), 6.76 (dd, J = 7.7Hz, 7.6Hz, 1H), 6.89-6.85 (m, 1H), 6.96 (dd, J = 8.9Hz, 8.8Hz, 1H), 7.05 (t, J = 3.3Hz, 2H), 7.16 (t, J = 3.6Hz, 3H), 8.82 (s, 1H); ¹³C **NMR (75 MHz, CDCl₃)** δ (**ppm**): 26.6, 31.0, 48.2, 70.7, 110.6, 110.7, 113.6, 113.9, 115.5, 115.8, 125.8,

127.2, 128.0, 128.2, 128.3, 132.8, 133.2, 138.7, 139.1, 156.0, 159.2, 178.9; **IR** (**KBr**): 3455, 2940, 3025, 2230, 1670 cm⁻¹; **ESI MS** (*m*/*z*): 321 (M+H)⁺. Anal. Calcd. for C₂₀H₁₇FN₂O: C, 74.98; H, 5.35; N, 8.74; Found: C, 74.99; H, 5.38; N, 8.71.

5-Iodo-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4f): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.66-1.56 (m, 2H), 1.96-1.88 (m, 1H), 2.19-2.12 (m, 1H), 2.75-2.70 (m, 2H), 4.75 (t, J = 7.2Hz, 1H), 6.60 (br, s, 1H), 6.75 (d, J = 8.2Hz, 1H), 7.03-7.00 (m, 2H), 7.17-7.15 (m, 4H), 7.57 (dd, J = 8.7Hz, 8.1Hz, 1H), 9.04 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 27.2, 31.8,

48.9, 71.6, 84.9, 113.1, 126.1, 127.8, 128.5, 129.5, 132.9, 133.2, 135.3, 138.5, 139.4, 141.5, 181.0; **IR** (**KBr**): 3477, 2920, 3045, 2209, 1675 cm⁻¹; **ESI MS** (*m*/*z*): 429 (M+H)⁺. Anal. Calcd. for C₂₀H₁₇IN₂O: C, 56.09; H, 4.00; N, 6.54; Found: C, 56.15; H, 4.01; N, 6.52.

1-Methyl-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4g): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.61-1.54 (m, 1H), 1.81 (br, s, 2H), 2.73 (t, J = 7.4Hz, 2H), 3.19 (s, 3H), 4.73 (br, s, 1H), 6.44 (s, 1H), 6.81 (br, 3H), 7.02-6.87 (m, 5H), 7.27-7.20 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ (**ppm**): 10.5, 19.7, 26.4, 28.9, 31.0, 41.0, 48.0, 70.7, 78.3, 108.0, 121.1, 125.6, 125.8, 126.2, 126.7, 127.3, 128.7, 132.1, 132.9, 139.7, 143.3, 177.2; **IR** (**KBr**):

3465, 2921, 3020, 2200, 1680 cm⁻¹; **ESI MS** (*m/z*): 317 (M+H)⁺. Anal. Calcd. for C₂₁H₂₀N₂O: C, 79.72; H, 6.37; N, 8.85; Found: C, 79.74; H, 6.33; N, 8.86.

1-Ethyl-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4h): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.36 (t, J = 6.9Hz, 3H), 1.59-1.50 (m, 1H), 1.80-1.70 (m, 2H), 2.09-2.04 (m, 1H), 2.69-2.63 (m, 2H) 3.84 (q, J = 6.8Hz, 2H), 4.69 (t, J = 6.4Hz, 1H), 6.51 (br, s, 1H),6.95-6.84 (m, 5H), 7.18-7.01 (m, 4H); **IR** (**KBr**): 3463, 2919, 3021, 2205, 1678 cm⁻¹; **ESI MS** (*m*/*z*): 331 (M+H)⁺. Anal. Calcd. for C₂₂H₂₂N₂O: C, 79.97; H, 6.71; N, 8.48; Found: C,

79.99; H, 6.69; N, 8.49.

3-(2-(Phenylethynyl)pyrrolidin-1-yl)-1-propylindolin-2-one (4i): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 0.94 (t, J = 7.4Hz, 3H), 1.72-1.63 (m, 3H), 1.88-1.84 (m, 2H), 2.15-2.07 (m, 1H), 2.74-2.68 (m, 2H), 3.79-3.57 (m, 2H), 4.75 (t, J = 7.1 Hz, 1H), 6.49 (s, 1H), 6.86 (d, J = 8.7Hz, 1H), 6.92-6.90 (m, 2H), 7.07-6.95 (m, 5H), 7.30-7.26 (m, 1H); ¹³C **NMR (75 MHz, CDCl₃)** δ (**ppm**): 10.5, 19.7, 26.4, 28.9, 31.0, 41.0, 48.0, 70.7, 78.3, 108.0, 121.1,

125.6, 125.8, 126.2, 126.7, 127.3, 128.7, 132.1, 132.9, 139.7, 143.3, 177.2; **IR** (**KBr**): 3440, 2910, 3027, 2225, 1677 cm⁻¹; **ESI MS** (*m*/*z*): 345 (M+H)⁺. Anal. Calcd. for C₂₃H₂₄N₂O: C, 80.20; H, 7.02; N, 8.13; Found: C, 80.23; H, 7.01; N, 8.12.

1-Butyl-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4j): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 0.88 (t, J = 7.3 Hz, 1H), 1.31-1.22 (m, 2H), 1.61-1.56 (m, 3H), 1.85 (d, J = 6.2Hz, 2H), 2.13-2.08 (m, 1H), 2.73 (br, s, 2H), 3.65-3.55 (m, 1H), 3.76-3.69 (m, 1H), 4.76 (br, s, 1H), 6.42 (br, s, 1H), 6.86-6.80 (m, 3H), 6.91 (d, J = 6.9Hz, 1H), 7.02-6.95 (m, 4H), 7.24-7.19 (m, 1H); **IR** (**KBr**): 3420, 2930, 3019, 2229, 1681 cm⁻¹; **ESI MS** (m/z): 359 (M+H)⁺. Anal. Calcd. for

C₂₄H₂₆N₂O: C, 80.41; H, 7.31; N, 7.81; Found: C, 80.44; H, 7.29; N, 7.82.

1-Benzyl-3-(2-(phenylethynyl)pyrrolidin-1-yl)indolin-2-one (4k): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.64-1.52 (m, 1H), 1.85 (br, s, 2H), 2.12-2.10 (m, 1H), 2.74 (d, J = 6.5Hz, 2H), 4.70 (d, J = 15.5Hz, 1H), 5.09 (d, J = 15.6Hz, 1H), 6.46 (s, 1H), 6.69 (d, J = 7.6Hz, 1H), 6.82 (d, J = 7.3Hz, 2H), 6.91 (t, J = 7.4Hz, 1H), 6.99-6.94 (m, 3H), 7.05 (d, J = 6.8Hz, 1H), 7.19-7.10 (m, 7H); **IR (KBr):** 3427, 2950, 3015, 2220, 1672 cm⁻¹; **ESI MS** (*m*/*z*): 393 (M+H)⁺. Anal. Calcd. for C₂₇H₂₄N₂O: C, 82.62; H, 6.16; N, 7.14; Found: C, 82.64; H, 6.13; N, 7.12.

3-(2-(p-Tolylethynyl)pyrrolidin-1-yl)indolin-2-one (4l): Physical state: solid; ¹H NMR (300 MHz,



CDCl₃) δ (**ppm**): 1.93-1.79 (m, 4H), 2.21 (s, 3H), 2.79-2.74 (m, 2H), 4.78 (t, J = 8.0Hz, 1H), 6.54 (br, s, 1H), 7.00-6.91 (m, 7H), 7.25-7.20 (m, 1H), 9.07 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (**ppm**): 20.3, 26.3, 31.1, 48.2, 70.7, 78.8, 110.3, 121.3, 125.3, 126.1, 126.2, 128.3, 128.8, 129.7, 131.2,

136.6, 139.1, 141.2, 180.5; **IR (KBr):** 3455, 2960, 3054, 2264, 1676 cm⁻¹; **ESI MS** (*m/z*): 317 (M+H)⁺. Anal. Calcd. for C₂₁H₂₀N₂O: C, 79.72; H, 6.37; N, 8.85; Found: C, 79.74; H, 6.34; N, 8.83.

3-(2-(m-Tolylethynyl)pyrrolidin-1-yl)indolin-2-one (4m): Physical state: solid; ¹H NMR (300 MHz,



CDCl₃) δ (**ppm**): 1.90-1.72 (m, 4H), 2.24 (s, 3H), 2.80-2.73 (m, 2H), 4.77 (t, J = 8.1Hz, 1H), 6.51 (br, s, 1H), 7.03-6.94 (m, 6H), 7.28-7.19 (m, 1H), 7.75 (s, 1H), 9.09 (s, 1H); **IR** (**KBr**): 3458, 2970, 3025, 2245, 1679 cm⁻¹; **ESI MS** (*m*/*z*): 317 (M+H)⁺. Anal. Calcd. for C₂₁H₂₀N₂O: C, 79.72; H, 6.37; N, 8.85; Found: C, 79.73; H, 6.34; N, 8.84.

Methyl 3-(1-(2-oxoindolin-3-yl)pyrrolidin-2-yl)propiolate (4n): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 2.24-1.80 (m, 4H), 2.67 (t, J = 6.6Hz, 2H), 3.47 (s, 3H), 4.66 (t, J = 7.3Hz, 1H), 6.94-6.83 (m, 3H), 7.19-7.14 (m, 2H), 8.35 (s, 1H); ¹³C **NMR (75 MHz, CDCl₃)** δ (**ppm**): 22.0, 30.6, 31.2, 47.6, 51.0, 71.6, 110.1, 121.2, 125.2, 125.8, 129.1, 133.4, 141.5, 146.0, 161.9, 179.5; **IR (KBr)**:

3480, 2967, 3025, 2325, 1723, 1680 cm⁻¹; **ESI MS** (*m*/*z*): 285 (M+H)⁺. Anal. Calcd. for C₁₆H₁₆N₂O₃: C, 67.59; H, 5.67; N, 9.85; Found: C, 67.62; H, 5.69; N, 9.83.

2-(2-(Phenylethynyl)pyrrolidin-1-yl)acenaphthylen-1(2H)-one (6a): Physical state: solid; ¹H NMR



(300 MHz, CDCl₃) δ (ppm): 1.78-1.61 (m, 4H), 2.46 (br, s, 1H), 2.65 (br, s, 1H), 4.76 (br, s, 1H), 6.55 (s, 1H), 6.72 (d, J = 7.1Hz, 1H), 6.94-6.85 (m, 3H), 7.23 (t, J = 6.9Hz, 1H), 7.51 (t, J = 8.1Hz, 1H), 7.74 (t, J = 7.6Hz, 1H), 7.84 (d, J = 8.2Hz, 1H), 8.06-8.02 (m, 2H); **IR (KBr):** 3029, 2980, 2201, 1720 cm⁻¹; **ESI MS** (m/z): 338 (M+H)⁺. Anal. Calcd. for C₂₄H₁₉NO: C, 85.43; H, 5.68; N,

4.15; Found: C, 85.46; H, 5.66; N, 4.12.





(300 MHz, CDCl₃) δ (ppm): 1.81-1.67 (m, 4H), 2.12 (s, 3H), 2.46-2.35 (m, 1H), 2.66-2.61 (m, 1H), 4.77 (br, 1H), 6.58 (s, 1H), 6.68 (d, J = 7.8Hz, 2H), 6.76 (d, J = 7.8Hz, 2H), 7.29 (br, 1H), 7.58 (t, J = 7.3Hz, 1H), 7.79 (t, J = 7.6Hz, 1H), 7.89 (d, J = 8.4Hz, 1H), 8.14 (dd, J = 8.2Hz, 6.7Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 20.1, 21.8, 25.7, 28.8, 30.4, 31.1, 32.9,

49.0, 69.8, 81.8, 113.2, 122.0, 122.6, 124.5, 125.3, 127.2, 127.4, 127.9, 130.0, 130.1, 130.5, 131.4, 131.7, 135.3, 136.2, 138.4, 139.1, 141.6, 202.1; **IR (KBr):** 3030, 2970, 2265, 1718 cm⁻¹; **ESI MS** (*m/z*): 352 (M+H)⁺. Anal. Calcd. for C₂₅H₂₁NO: C, 85.44; H, 6.02; N, 3.99; Found: C, 85.48; H, 6.01; N, 3.94.

2-(2-(Phenylethynyl)pyrrolidin-1-yl)aceanthrylen-1(2H)-one (8a): Physical state: solid; ¹H NMR (300



MHz, CDCl₃) δ (**ppm**): 1.82-1.60 (m, 3H), 2.15-2.08 (m, 1H), 2.45-2.40 (m, 1H), 2.69-2.61 (m, 1H), 4.79 (t, J = 6.6Hz, 1H), 6.61 (s, 1H), 6.91-6.76 (m, 5H), 7.47 (t, J = 8.4Hz, 1H), 7.61 (t, J = 7.5Hz, 1H), 7.72 (t, J = 7.5Hz, 1H), 7.93 (d, J = 8.6Hz, 1H), 8.13 (d, J = 8.4Hz, 1H), 8.65 (s, 1H), 9.21 (d, J = 8.6Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 26.6, 31.4, 50.1, 70.9,

83.0, 123.0, 125.3, 125.6, 125.7, 126.3, 126.7, 127.3, 128.2, 128.6, 129.1, 129.4, 132.4, 133.6, 133.7, 134.0, 136.5, 140.3, 203.5; **IR** (**KBr**): 3031, 2975, 2260, 1721 cm⁻¹; **ESI MS** (*m*/*z*): 388 (M+H)⁺. Anal. Calcd. for C₂₈H₂₁NO: C, 86.79; H, 5.46; N, 3.61; Found: C, 86.81; H, 5.44; N, 3.59.

2-(2-(*p***-Tolylethynyl)pyrrolidin-1-yl)aceanthrylen-1(2***H***)-one (8b): Physical state: solid; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.86-1.69 (m, 3H), 2.07 (s, 3H) 2.19-2.14 (m, 1H), 2.50-2.45 (m, 1H), 2.73-**



2.65 (m, 1H), 4.83 (t, J = 7.2Hz, 1H), 6.62 (s, 1H), 6.73 (t, J = 8.8Hz, 4H), 7.24 (d, J = 4.6Hz, 1H), 7.53 (t, J = 8.4Hz, 1H), 7.65 (t, J = 7.4Hz, 1H), 7.76 (t, J = 7.8Hz, 1H), 7.98 (d, J = 8.6Hz, 1H), 8.18 (d, J = 8.4Hz, 1H), 8.70 (s, 1H), 9.25 (d, J = 8.5Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 20.2, 25.8, 28.9, 30.6, 49.2, 70.2, 82.2, 122.2, 124.5, 124.7, 124.9,

125.3, 125.8, 126.5, 127.8, 128.0, 128.2, 128.4, 130.3, 131.5, 131.9, 132.8, 135.8, 136.2, 139.3, 143.7, 202.8; **IR** (**KBr**): 3032, 2960, 2255, 1719 cm⁻¹; **ESI MS** (*m*/*z*): 402 (M+H)⁺. Anal. Calcd. for C₂₉H₂₃NO: C, 86.75; H, 5.77; N, 3.49; Found: C, 86.78; H, 5.74; N, 3.48.

2-(2-((4-(Tert-butyl)phenyl)ethynyl)pyrrolidin-1-yl)aceanthrylen-1(2H)-one(8c): Physical state:



solid; ¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.10 (s, 9H), 1.88-1.74 (m, 3H), 2.19-2.13 (m, 1H), 2.52-2.47 (m, 1H), 2.69 (t, *J* = 8.4Hz, 1H), 4.83 (t, *J* = 7.5Hz, 1H), 6.68 (s, 1H), 6.77 (d, *J* = 8.3Hz, 2H), 6.93 (d, *J* = 8.3Hz, 2H), 7.30 (t, *J* = 6.6Hz, 1H), 7.56 (d, *J* = 6.8Hz, 1H), 7.67 (d, *J* = 7.6Hz, 1H), 7.78 (d, *J* = 7.9Hz, 1H), 8.01 (d, *J* = 8.6Hz, 1H), 8.20 (d, *J* = 8.4Hz,

1H), 8.73 (s, 1H), 9.26 (d, J = 8.5Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ (ppm): 25.5, 29.9, 30.4, 33.2,

48.7, 69.8, 81.6, 121.8, 123.9, 124.2, 124.4, 124.5, 124.6, 125.5, 126.2, 127.5, 127.8, 128.0, 129.6, 131.2, 131.5, 132.4, 135.5, 138.7, 143.3, 149.1, 202.5; **IR** (**KBr**): 3018, 2960, 2265, 1723 cm⁻¹; **ESI MS** (*m/z*): 444 (M+H)⁺. Anal. Calcd. for C₃₂H₂₉NO: C, 86.65; H, 6.59; N, 3.16; Found: C, 86.68; H, 6.58; N, 3.14. **2-(2-(Phenylethynyl)pyrrolidin-1-yl)-1***H***-indene-1,3(2***H***)-dione(10a): Physical state: solid; ¹H NMR (300 MHz, CDCl₃) \delta (ppm): 2.29-2.12 (m, 2H), 2.70 (t,** *J* **= 8.3Hz, 3H), 3.34-3.26 (m, 1H), 5.93 (s, 1H),**



6.58 (s, 1H), 7.24-7.19 (m, 2H), 7.35 (d, J = 7.2Hz, 2H), 7.45 (t, J = 7.3Hz, 2H), 7.51 (d, J = 7.3Hz, 1H), 7.60 (t, J = 7.1Hz, 1H), 7.91 (t, J = 7.4Hz, 1H); ¹³**C NMR** (75 MHz, CDCl₃) δ (ppm): 22.9, 26.5, 44.8, 99.4, 115.0, 122.4, 124.6, 125.6, 126.0, 127.7, 127.9, 128.6, 132.2, 133.4, 135.4, 138.7, 147.3, 169.5; **IR** (**KBr**): 3040, 2961, 2280, 1722 cm⁻¹; **ESI MS** (*m*/*z*): 316 (M+H)⁺. Anal. Calcd. for C₂₁H₁₇NO₂: C, 79.98; H, 5.43; N, 4.44; Found: C, 79.99; H, 5.41; N, 4.41.

Spectral data (1H NMR and 13C NMR) of all the synthesised compounds.



Figure 1. ¹H Spectrum of 4a



Figure 3. ¹H Spectrum of 4b



Figure 4. ¹³C Spectrum of 4b



Figure 5. ¹H Spectrum of 4c



Figure 6. ¹³C Spectrum of 4c



Figure 7. ¹H Spectrum of 4d



Figure 8. ¹³C Spectrum of 4d



Figure 9. ¹H Spectrum of 4e



Figure 10. ¹³C Spectrum of 4e



Figure 11. ¹H Spectrum of 4f



Figure 12. ¹³C Spectrum of 4f



Figure 13. ¹H Spectrum of 4g



Figure 14. ¹³C Spectrum of 4g



Figure 15. ¹H Spectrum of 4h



Figure 16. ¹H Spectrum of 4i



Figure 17. ¹³C Spectrum of 4i



Figure 18. ¹H Spectrum of 4j



Figure 19. ¹H Spectrum of 4k



Figure 20. ¹H Spectrum of 41



Figure 21. ¹³C Spectrum of 41



Figure 22. ¹H Spectrum of 4m



Figure 23. ¹H Spectrum of 4n



Figure 24. ¹³C Spectrum of 4n



Figure 25. ¹H Spectrum of 6a



Figure 26. ¹H Spectrum of 6b



Figure 27. ¹³C Spectrum of 6b



Figure 28. ¹H Spectrum of 8a



Figure 29. ¹³C Spectrum of 8a



Figure 30. ¹H Spectrum of 8b



Figure 31. ¹³C Spectrum of 8b



Figure 32. ¹H Spectrum of 8c



Figure 33. ¹³C Spectrum of 8c



Figure 34. ¹H Spectrum of 10a



Figure 35. ¹³C Spectrum of 10a